Gainers & Losers Of Mar.14: CVRS, OCX, OFIX, PETX, AMPH...

(RTTNews) - The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of March 14, 2017.

GAINERS

1. Neovasc Inc. (NVCN)

Gained 27.14% to close Tuesday's (Mar.14) trading at $1.78.

News: No news

Near-term catalyst: The Company will release its financial results for the fourth quarter and fiscal year 2016 on Thursday, March 23, 2017, after markets close.

Analysts polled by Thomson Reuters expect the company to incur a loss of $0.09 per share on revenue of $2.63 million for Q4, 2016, and a loss of $1.48 per share on revenue of $9.2 million for full-year 2016.

Neovasc's products include Neovasc Reducer, for the treatment of refractory angina which is not currently available in the U.S. and has been available in Europe since 2015 and the Tiara, for the transcatheter treatment of mitral valve disease, which is currently under investigation in the U.S., Canada and Europe.

2. Corindus Vascular Robotics Inc. (CVRS)

Gained 19.49% to close Tuesday's trading at $1.41.

News: No news

Near-term catalyst: The Company will release financial and business results for the fourth quarter and full year 2016 after the close of trading on Wednesday, March 15, 2017.

The consensus estimate of analysts polled by Thomson Reuters calls for a loss of $0.07 per share on revenue of $770 thousand for Q4, 2016, and a loss of $0.27 per share on revenue of $3.07 million for full-year 2016.

The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary interventions.

3. OncoCyte Corporation (OCX)

Gained 15.15% to close Tuesday's trading at $5.70.

News: No news

Near-term catalysts:

-- The Company will be presenting key performance metrics of its blood based lung cancer test at the American Thoracic Society Meeting in May. -- The lung cancer diagnostic test is expected to be launched during the second half of 2017.

4. Clovis Oncology Inc. (CLVS)

Gained 15.15% to close Tuesday's trading at $5.70.

News: No news

Near-term catalysts:

-- Data from a phase III trial of Rucaparib as maintenance treatment following platinum-based therapy in women with platinum-sensitive, relapsed, high grade serous or endometrioid ovarian fallopian tube, or primary peritoneal cancer, dubbed ARIEL3, are expected mid-2017.

Rucaparib was approved as recently as last December for the treatment of advanced mutant BRCA ovarian cancer.

-- Rucaparib is under review in the European Union and an opinion from the Committee for Medicinal Products for Human Use (CHMP) is expected in late 2017.

5. Neuralstem Inc. (CUR)

Gained 10.28% to close Tuesday's trading at $5.90.

News: No news

Near-term catalysts:

The company's lead clinical program is NSI-189, which is under phase II clinical trial for the treatment of major depressive disorder. Results from this study are expected in the 3Q of 2017, and results from the subsequent, 6-month observational study to assess NSI-189's durability effect will be available in the first half of 2018.

6. Orthofix International N.V. (OFIX)

Gained 9.88% to close Tuesday's trading at $38.37.

News: Orthofix is all set to join S&P SmallCap 600 index effective prior to the open of trading on Thursday, March 16, 2017.

7. Aptevo Therapeutics Inc. (APVO)

Gained 9.34% to close Tuesday's trading at $1.99.

News: Preclinical data on new anti-CD123 ADAPTIR bispecific candidates to be presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting on April 2, 2017.

Near-term catalysts:

- Preliminary results from the ongoing dose-escalation phase I study of MOR209/ES414 monotherapy in patients with metastatic castration-resistant prostate cancer due in mid-2017. - Preliminary data read-out from a phase II study of Otlertuzumab in combination with Ibrutinib for chronic lymphocytic leukemia are anticipated in the second half of 2017.

8. Acasti Pharma Inc. (ACST)

Gained 7.44% to close Tuesday's trading at $1.30.

News: No news

Near-term catalyst: The Company is preparing to advance CaPre, an investigational drug for the treatment of hypertriglyceridemia, into a phase III clinical trial. In January of this year, it was reported that the Company has an End of phase II meeting scheduled with the FDA in the first quarter of 2017 related to CaPre.

Positive data from the company's phase II Bridging Study for CaPre were reported last September.

LOSERS

1. Anthera Pharmaceuticals, Inc. (ANTH)

Lost 39.64% to close Tuesday's trading at $0.41.

News: The Company has priced its underwritten public offering of 30 million shares of its common stock at a price of $0.50 per share and two tranches of warrants to purchase an aggregate of 60 million shares of its common stock.

The gross proceeds to the Company from the offering are expected to be $15.0 million. The offering is expected to close on or about March 17, 2017.

2. Aurinia Pharmaceuticals Inc. (AUPH)

Lost 25.05% to close Tuesday's trading at $7.90.

News: The Company has offered to sell 22.3 million common shares to the public at a price of US$6.75 per share.

The gross proceeds from the offering are expected to be approximately US$150.5 million. The offering is expected to close on or about March 20, 2017, subject to the satisfaction of customary closing conditions.

3. Aratana Therapeutics Inc. (PETX)

Lost 23.45% to close Tuesday's trading at $5.32.

News: Fourth quarter and full year 2016 financial results released.

The fourth quarter net loss widened to $23.3 million or $0.64 per share from $12.9 million or $0.37 per share for the corresponding quarter ended December 31, 2015. For the year ended December 31, 2016, Aratana reported a net loss of $33.6 million or $0.95 per share compared to a net loss of $84.1 million or $2.45 per share in 2015.

Aratana had $292 thousand in net revenue for the quarter ended December 31, 2016, which includes Nocita sales after becoming commercially available in late 2016, and $38.6 million in net revenue for the full year of 2016, which was generated largely from the upfront payment related to the collaboration agreement with Elanco. This compared with revenue of $63 thousand and $678 thousand in Q4, 2015 and full-year of 2015, respectively.

4.Amphastar Pharmaceuticals Inc. (AMPH)

Lost 17.23% to close Tuesday's trading at $12.20.

News: The Company has reported Q4 and full-year 2016 financial results

Amphastar's Q4, 2016 revenue was $63.5 million, a decrease of 17% compared to $76.9 million in the year-ago quarter.

GAAP net loss was $2.7 million or $0.06 per share and adjusted non-GAAP net income was $0.5 million or $0.01 per share in the fourth quarter of 2016. This compared with GAAP net income of $7.53 million or $0.16 per share and adjusted non-GAAP net income of $9.07 million or $0.19 per share in the year-ago quarter.

5. Aralez Pharmaceuticals Inc. (ARLZ)

Lost 15.04% to close Tuesday's trading at $2.09, plunging for second straight day.

News: The Company announced disappointing 2016 results and guided 2017 revenue way below analysts' expectations on March 13, 2017.

Total net revenues for the three months ended December 31, 2016 skyrocketed to $20.0 million from $6.0 million in the comparable year-ago quarter. However, analysts polled by Thomson Reuters expected revenue of $23.12 million.

For 2017, Aralez foresees net revenues to be in a range of $80 million to $100 million, well below analysts' expatiations of $145.14 million.

6. Pulmatrix Inc. (PULM)

Lost 14.29% to close Tuesday's trading at $2.76.

News: No news

Near-term catalysts:

-- The Company expects pre-clinical data on PUR1900 targeting fungal infections for severe asthma and cystic fibrosis patients in the first half of 2017 -- Secure a strategic partner(s) on PUR0200, the company's most-advanced drug candidate, in the first half of 2017

PUR0200, is a novel dry powder formulation of a currently marketed once daily LAMA bronchodilator Spiriva HandiHaler, for the treatment of chronic obstructive pulmonary disease. PUR0200 is currently being developed in Europe based on PK bioequivalence, and the US development program is being planned.

-- Pulmatrix intends to seek a pre-IND meeting with the FDA to inform the US clinical development path for PUR0200 in the second half of 2017. -- Continue CMC development work in the first half of 2017 to support a future European pivotal pharmacokinetic bioequivalence approval study as well as the US development path.